GlassScriptPhysician profile
Xiao C Wan
NPI 1295099042
$1,130.44
in general payments reported to CMS, 2019-2025
11 companies · $46.41 in 2025
The $46.41 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $211 · 2020: $375 · 2021: $102 · 2022: $45.99 · 2023: $43.75 · 2024: $307 · 2025: $46.41.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $367 · Education: $30.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $366.54 |
| Education | $30.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $227.59 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $207.25 | 2020-2024 | Tezspire |
| Genzyme Corporation | $204.58 | 2019-2024 | |
| Alk-Abello, INC | $199.99 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $122.54 | 2024 | Lifevest |
| Novartis Pharmaceuticals Corporation | $46.41 | 2025 | |
| Pfizer INC. | $43.75 | 2023 | |
| Csl Behring | $25.00 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.95 | 2024 | Cuvitru |
| Regeneron Healthcare Solutions, INC. | $15.41 | 2019 | |
| Horizon Therapeutics Plc | $12.97 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Xiao Wan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.